BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26327325)

  • 1. CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer.
    Paret C; Simon P; Vormbrock K; Bender C; Kölsch A; Breitkreuz A; Yildiz Ö; Omokoko T; Hubich-Rau S; Hartmann C; Häcker S; Wagner M; Roldan DB; Selmi A; Türeci Ö; Sahin U
    Oncotarget; 2015 Sep; 6(28):25356-67. PubMed ID: 26327325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
    Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
    Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
    Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.
    Peng S; Trimble C; He L; Tsai YC; Lin CT; Boyd DA; Pardoll D; Hung CF; Wu TC
    Gene Ther; 2006 Jan; 13(1):67-77. PubMed ID: 16107858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
    Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
    PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.
    Olson BM; Frye TP; Johnson LE; Fong L; Knutson KL; Disis ML; McNeel DG
    Cancer Immunol Immunother; 2010 Jun; 59(6):943-53. PubMed ID: 20140431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Schmidt J; Guillaume P; Dojcinovic D; Karbach J; Coukos G; Luescher I
    J Biol Chem; 2017 Jul; 292(28):11840-11849. PubMed ID: 28536262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.
    Straetemans T; van Brakel M; van Steenbergen S; Broertjes M; Drexhage J; Hegmans J; Lambrecht BN; Lamers C; van Der Bruggen P; Coulie PG; Debets R
    Clin Dev Immunol; 2012; 2012():586314. PubMed ID: 22400038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
    Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.
    Liu L; Wang Y; Miao L; Liu Q; Musetti S; Li J; Huang L
    Mol Ther; 2018 Jan; 26(1):45-55. PubMed ID: 29258739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors.
    Hung CF; Calizo R; Tsai YC; He L; Wu TC
    Vaccine; 2007 Jan; 25(1):127-35. PubMed ID: 16930783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
    Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
    Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo.
    Willimsky G; Beier C; Immisch L; Papafotiou G; Scheuplein V; Goede A; Holzhütter HG; Blankenstein T; Kloetzel PM
    Elife; 2021 Apr; 10():. PubMed ID: 33875134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avidity characterization of genetically engineered T-cells with novel and established approaches.
    Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
    BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
    Kissick HT; Sanda MG; Dunn LK; Arredouani MS
    PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunopeptidomic Profiling of HLA-A2-Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target Antigens.
    Ternette N; Olde Nordkamp MJM; Müller J; Anderson AP; Nicastri A; Hill AVS; Kessler BM; Li D
    Proteomics; 2018 Jun; 18(12):e1700465. PubMed ID: 29786170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of NY-ESO-1
    Zhang H; Sun M; Wang J; Zeng B; Cao X; Han Y; Tan S; Gao GF
    Front Immunol; 2021; 12():644520. PubMed ID: 33833762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
    Zhou X; Jun DY; Thomas AM; Huang X; Huang LQ; Mautner J; Mo W; Robbins PF; Pardoll DM; Jaffee EM
    Cancer Res; 2005 Feb; 65(3):1079-88. PubMed ID: 15705910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients.
    Gnjatic S; Jäger E; Chen W; Altorki NK; Matsuo M; Lee SY; Chen Q; Nagata Y; Atanackovic D; Chen YT; Ritter G; Cebon J; Knuth A; Old LJ
    Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11813-8. PubMed ID: 12186971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.